Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Ito

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
JTO Clinical and Research Reports|January 17, 2024
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid CarcinomaDaisuke Hazama, Kenji Nakahama, Hiroaki Kodama, et al.
Frontiers in Neuroscience|July 19, 2019
STEFTR: A Hybrid Versatile Method for State Estimation and Feature Extraction From the Trajectory of Animal BehaviorShuhei J Yamazaki, Kazuya Ohara, Kentaro Ito, et al.
Journal of Medicinal Chemistry|December 26, 2022
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase InhibitorRyutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, et al.
Cancer Medicine|April 17, 2024
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitorsTadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, et al.
Cancer Science|July 9, 2020
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world dataKentaro Ito, Kenta Murotani, Akihito Kubo, et al.
The Journal of Clinical Investigation|October 3, 2023
A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>TKentaro Ito, Go Tajima, Chikako Kamisato, et al.
Cancers|August 26, 2022
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and ChemotherapyTadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, et al.
Scientific Reports|March 6, 2023
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancerDaichi Fujimoto, Satoru Miura, Keisuke Tomii, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world settingRyosuke Tsugitomi, Kento Takagi, Go Saito, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
JTO Clinical and Research Reports|January 17, 2024
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid CarcinomaDaisuke Hazama, Kenji Nakahama, Hiroaki Kodama, et al.
Frontiers in Neuroscience|July 19, 2019
STEFTR: A Hybrid Versatile Method for State Estimation and Feature Extraction From the Trajectory of Animal BehaviorShuhei J Yamazaki, Kazuya Ohara, Kentaro Ito, et al.
Journal of Medicinal Chemistry|December 26, 2022
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase InhibitorRyutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, et al.
Cancer Medicine|April 17, 2024
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitorsTadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, et al.
Cancer Science|July 9, 2020
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world dataKentaro Ito, Kenta Murotani, Akihito Kubo, et al.
The Journal of Clinical Investigation|October 3, 2023
A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>TKentaro Ito, Go Tajima, Chikako Kamisato, et al.
Cancers|August 26, 2022
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and ChemotherapyTadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, et al.
Scientific Reports|March 6, 2023
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancerDaichi Fujimoto, Satoru Miura, Keisuke Tomii, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world settingRyosuke Tsugitomi, Kento Takagi, Go Saito, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.
Pageof 17